TY - JOUR
T1 - Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)
AU - Bashir, Qaiser
AU - Milton, Denái R.
AU - Popat, Uday R.
AU - Kebriaei, Partow
AU - Hosing, Chitra
AU - Khouri, Issa F.
AU - Rezvani, Katayoun
AU - Nieto, Yago
AU - Oran, Betul
AU - Srour, Samer A.
AU - Saini, Neeraj Y.
AU - Olson, Amanda L.
AU - Ahmed, Sairah
AU - Al-Atrash, Gheath
AU - Rondon, Gabriela
AU - Konopleva, Marina Y.
AU - Champlin, Richard E.
AU - Shpall, Elizabeth J.
AU - Qazilbash, Muzaffar H.
AU - Pemmaraju, Naveen
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/1
Y1 - 2022/1
N2 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematological malignancy; however, some patients achieve durable remission with allogeneic hematopoietic cell transplantation (allo-HCT). We report on all 17 patients with BPDCN who underwent allo-HCT at our center between 2000 and 2020. The median age was 39 (18–67) years. All (n = 16, 94%), except one patient, had systemic disease involving bone marrow and/or other organs. Ten patients (59%) were in first complete remission (CR1) at allo-HCT. The donor source was matched related or unrelated in ten (59%) and alternate donor in seven (41%) patients. Five (31%) patients developed acute graft-versus-host disease (GVHD), all grade I-II. The cumulative incidence (CI) of chronic GVHD at five-year was 34%. The CI of non-relapse mortality at one-year was 29%. Progression-free survival (PFS) rates at two-year and five-year were 49% (95% CI = 22–71%) and 39% (95% CI = 14–64%), respectively. The two-year and five-year overall survival (OS) rates were 65% (95% CI = 38–82%) and 40% (95% CI = 12–68%), respectively. The five-year rate for both PFS and OS was 80% in CR1 patients versus 0% in patients not in CR1. In conclusion, allo-HCT provides long-lasting remissions in BPDCN patients, particularly when performed in CR1.
AB - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematological malignancy; however, some patients achieve durable remission with allogeneic hematopoietic cell transplantation (allo-HCT). We report on all 17 patients with BPDCN who underwent allo-HCT at our center between 2000 and 2020. The median age was 39 (18–67) years. All (n = 16, 94%), except one patient, had systemic disease involving bone marrow and/or other organs. Ten patients (59%) were in first complete remission (CR1) at allo-HCT. The donor source was matched related or unrelated in ten (59%) and alternate donor in seven (41%) patients. Five (31%) patients developed acute graft-versus-host disease (GVHD), all grade I-II. The cumulative incidence (CI) of chronic GVHD at five-year was 34%. The CI of non-relapse mortality at one-year was 29%. Progression-free survival (PFS) rates at two-year and five-year were 49% (95% CI = 22–71%) and 39% (95% CI = 14–64%), respectively. The two-year and five-year overall survival (OS) rates were 65% (95% CI = 38–82%) and 40% (95% CI = 12–68%), respectively. The five-year rate for both PFS and OS was 80% in CR1 patients versus 0% in patients not in CR1. In conclusion, allo-HCT provides long-lasting remissions in BPDCN patients, particularly when performed in CR1.
UR - http://www.scopus.com/inward/record.url?scp=85116814512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116814512&partnerID=8YFLogxK
U2 - 10.1038/s41409-021-01478-5
DO - 10.1038/s41409-021-01478-5
M3 - Article
C2 - 34629467
AN - SCOPUS:85116814512
SN - 0268-3369
VL - 57
SP - 51
EP - 56
JO - Bone marrow transplantation
JF - Bone marrow transplantation
IS - 1
ER -